Take a look @ PTN... Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction. http://finance.yahoo.com/news/palatin-technologies-achieves-target-patient-123000132.html cl.